Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00070564Phase 3Active, not recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2003
- Primary completion
- Jan 2015
- Modality
- Targeted Liposomes, Cytokines & Interferons, Stealth (PEGylated) Liposomes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin, cyclophosphamide and Paclitaxel Micelles for Injection in breast cancer (6 arms), sponsored by SWOG Cancer Research Network. Primary endpoints: Disease-free Survival and Overall Survival. Started Nov 2003; status: active, not recruiting.
02
Drugs
pegylated liposomal doxorubicincyclophosphamidePaclitaxel Micelles for Injection
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00070564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070564.